-

08:50:00 PM

OGEN Stock News

OGEN - Oragenics Inc

09/15/21 7:30 AM

AMEX : OGEN

covid-19

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Oragenics, Inc. today announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the...

RHEA-AI

neutral

08/30/21 7:30 AM

AMEX : OGEN

Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants

Oragenics, Inc. announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the Company from the National Institutes of Health generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular and intranasal adjuvants.

RHEA-AI

positive

08/24/21 7:30 AM

AMEX : OGEN

Oragenics Announces Postponement of Annual Meeting of Shareholders

Oragenics, Inc. Oragenics, Inc. today announced the Company’ s reconvened annual meeting of shareholders, on August 23, 2021 at 4:00 p.m. was adjourned due to a lack of quorum. Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV...

RHEA-AI

neutral

07/27/21 7:00 AM

NYSE : OGEN

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants. The NRC

RHEA-AI

neutral

07/01/21 7:00 AM

NYSE : OGEN

Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced that the Company’s annual meeting of shareholders, on June 30, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.A quorum consists of a majority of

RHEA-AI

neutral

05/18/21 7:30 AM

NYSE : OGEN

Oragenics Issues Letter to Shareholders

Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, PhD:To My Fellow Shareholders,In light of the recent changes to the executive management team of Oragenics, I would like to affirm to our shareholders the

RHEA-AI

neutral

05/03/21 7:30 AM

NYSE : OGEN

management

Oragenics Announce Changes in Management and Board of Directors

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced that on May 2, 2021, Dr. Alan Joslyn resigned as Chief Executive Officer, President and director of Oragenics, Inc. to pursue other opportunities.During the interim period before a new CEO is hired, the Board of

RHEA-AI

neutral

03/09/21 7:00 AM

NYSE : OGEN

covid-19

Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance

RHEA-AI

positive

03/08/21 7:30 AM

NYSE : OGEN

conferences

Oragenics to Participate in Two Investment Conferences During March

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), today announced that Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, will participate in two virtual investment conferences during the month of March, as follows:The H.C. Wainwright Global Life Sciences

RHEA-AI

neutral

02/12/21 8:00 AM

NYSE : OGEN

Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately

RHEA-AI

neutral

OGEN Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.oragenics.com
Security nameOragenics Inc
Issue typecs
SectorManufacturing
Sic code2834
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address4902 Eisenhower Blvd Ste 125
StateFlorida
CityTampa
Zip33634-6342
CountryUS
Phone18132867900

OGEN Description:

Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.